A Bioequivalence Study of Sacubitril/Valsartan Film-coated Tablets Under Fasting Conditions

A Bioequivalence Study of Two Formulations of Sacubitril/Valsartan 49 mg/51 mg Film-coated Tablets in Healthy Thai Subjects Under Fasting Conditions

Primary objective is to is to evaluate the bioequivalence of two formulations

Study Overview

• Status: Not yet recruiting
• Conditions: Bioequivalence Study
• Intervention / Treatment: Drug: Sacubitril and Valsartan Tablets 49mg/51mg; Drug: Entresto® (Sacubitril and Valsartan Tablets 49mg/51mg)

Detailed Description

To evaluate the bioequivalence of two formulations of sacubitril/valsartan 49 mg/51 mg film coated tablets, Entresto® (Reference) and Sacubitril and Valsartan Tablets 49mg/51mg (Test), after a single oral dose administration in healthy Thai subjects under fasting conditions

• Study Type: Interventional
• Enrollment (Estimated): 48
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Venkatesh Daggumati, M.Pharm; Phone Number: 7032185444; Email: Venkatesh.Daggumati@viatris.com
• Study Contact Backup: Name: Arun Kumar, M.Pharm; Phone Number: 9676300054; Email: akumar@viatris.com

Study Locations

• Thailand
  • Bangkok, Thailand, 10310
    • Medica Innova Co Ltd
    • Contact: Ariya Khunvichai, Ph.D; Phone Number: 666 2428 7178; Email: ariya@medicainnova.com
    • Principal Investigator: Suvimol Niyomnaitham, Assist. Prof., M.D., Ph.D.

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

1. Thai Male/Female must be 18-55 years of age, body weight > 50.0 kg with body mass index (BMI) = 18.0-30.0 kg/m2, inclusive.
2. Must be in good health as determined by medical history, vital signs (blood pressure (systolic blood pressure not lower than 100 or not over 139 mmHg, diastolic blood pressure not lower than 70 or not over 89 mmHg), body temperature, pulse rate, respiratory rate) and physical examination or showing no clinically significant abnormalities in the opinion of Principal/Clinical Investigator or designated physicians
3. Screening ECG without clinically significant abnormalities
4. Screening visit laboratory values of blood test including hematology (CBC with differential), FBS (Fasting Blood sugar), BUN (Blood urea Nitrogen), Cr, and liver function test (AST (Aspartate transaminase), ALT (Alanine transaminase) , total bilirubin and ALP (Alkaline phosphatase) must be within the normal range or showing no clinically significant abnormalities in the opinion of Principal/Clinical Investigator or designated physicians.
5. Urinalysis results within normal limit or showing no clinically significant abnormalities in the opinion of Principal/Clinical Investigator or designated physicians.
6. Must have serum HBsAg, anti-HCV and anti-HIV negative
7. Female subject must have serum β-hCG negative or showing no clinically significant abnormalities in the opinion of Principal/Clinical Investigator or designated physicians.
8. Subject willing to avoid or follow precautions while driving, operating machinery and while working on high elevations.
9. Female subject of childbearing potential or male subject agrees to use an acceptable birth control method from screening visit to the followup visit. The acceptable birth control method is defined as a barrier method of contraception (including condoms, intrauterine device and diaphragm with spermicidal agent) or total abstinence from sexual intercourse from visit 1 to the follow-up visit. Hormonal contraceptives are not acceptable.
10. Female subject of non-childbearing potential (hysterectomy, both ovaries removed, surgically sterilized or postmenopausal (for at least 12 consecutive months of amenorrhea))
11. Female subject must agree not to become pregnant for the entire participation period and must have a negative result for a urine pregnancy test performing prior to dosing at Period 1, Period 2, Period 3 and Period 4.
12. Non-smoker (never smoked or no smoking within the previous 1 year)
13. Subject willing to not participate in blood donations (≥500 mL) until 56 days after completion of the study (last subject visit) and willing to not participate in clinical research studies until 30 days after completion of the study (last subject visit).
14. Refrain from using herbal medications, cannabis containing products, dietary supplements (e.g., St. John's Wort, ginkgo biloba, garlic supplements), vitamins, grapefruit or grapefruit juice, or pomelo within 14 days before the first administration of investigational product (Day 1). Subjects must agree to refrain from these items until the last collection time-point of Period 4.
15. Subject must have ended any systemic medications or any medications that have any impact on gastrointestinal system at least 30 days prior to Day 1 or at least 5 times of elimination half-life prior to Day 1 and agree to continue their refraining throughout the follow-up period.
16. Subject must refrain from drinking caffeine and alcohol for at least 48 hours prior to Day 1 and agree to continue their refraining throughout the last collection time-point of Period 4.
17. Have the ability to understand the requirements of the study and must voluntarily sign and date an informed consent, approved by an Independent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to the initiation of any screening or study-specific procedures.

Exclusion Criteria:

1. Known hypersensitivity to sacubitril or valsartan or any other similar class of drugs or its components
2. Past medical history of renal and hepatic insufficiency
3. Subject has a history of any illness that, in the opinion of Principal/Clinical Investigator or designated physicians, might confound the result of the study or pose an additional risk in administering investigational product to the subject. This may include but is not limited to: a history of relevant drug or food allergies; history of cardiovascular, gastrointestinal, central nervous system disease, renal and hepatic impairment; history or presence of clinically significant illness; or history of mental illness that may affect compliance with study requirements.
4. History of hereditary or idiopathic angioedema
5. Have a history of angioedema related to previous ACE inhibitor or ARB therapy
6. Have history of drug abuse (in the opinion of Principal/Clinical Investigator or designated physicians, as judged by medical history) in the last 12 months
7. Have positive result of urine drug abuse testing on opioids (Mor, MTD), cannabinoids (THC), Meth, Coc or MDMA at screening visit or before dose administration at each period
8. Alcohol abuse or excessive use (in the opinion of Principal/Clinical Investigator or designated physicians, as judged by medical history) in the last 12 months
9. Have positive result of alcohol breathing test at screening visit or before dose administration at each period
10. Female subject is pregnant or breast feeding.
11. Difficulties fasting or consuming standard meals
12. Difficulties swallowing whole tablets

13. Donation or loss of whole blood:

    1. ≥50 mL and ≤499 mL within 30 days prior to Day 1
    2. ≥500 mL within 56 days prior to Day 1
14. Participation in any investigational drug study within 30 days from screening visit (from the last follow-up visit to the screening visit).

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Health Services Research
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Test Product; Sacubitril and Valsartan Tablets 49mg/51mg to be orally administered	Drug: Sacubitril and Valsartan Tablets 49mg/51mg; Each tablet contains Sacubitril 49 mg and Valsartan 51 mg
Active Comparator: Reference product; Entresto® (48.6 mg sacubitril and 51.4 mg valsartan as sodium salt complex) to be orally administered	Drug: Entresto® (Sacubitril and Valsartan Tablets 49mg/51mg); Each tablet contains 48.6 mg sacubitril and 51.4 mg valsartan as sodium salt complex

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Cmax	Peak Plasma Concentration	4 months
AUC	Area under the plasma concentration	4 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
tmax	Time to reach Cmax	4 months
t1/2	apparent terminal elimination half-life	4 months
λz	apparent terminal elimination rate constant	4 months
AUC0-t/AUC0-∞	Ratio of Area under the curves	4 months
residual area	residual area	4 months

Collaborators and Investigators

• Sponsor: Viatris Inc.
• Investigators: Study Director: Ariya Khunvichai, Ph.D, Medica Innova Co., Ltd.

Study record dates

Study Major Dates

• Study Start (Estimated): April 1, 2024
• Primary Completion (Estimated): May 1, 2024
• Study Completion (Estimated): September 1, 2024

Study Registration Dates

• First Submitted: February 14, 2024
• First Submitted That Met QC Criteria: February 14, 2024
• First Posted (Estimated): February 22, 2024

Study Record Updates

• Last Update Posted (Estimated): February 22, 2024
• Last Update Submitted That Met QC Criteria: February 14, 2024
• Last Verified: February 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Molecular Mechanisms of Pharmacological Action; Antihypertensive Agents; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Valsartan; Sacubitril and valsartan sodium hydrate drug combination
• Other Study ID Numbers: SCVL-TFZ-1009

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No